Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinicalstage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming industry and investor conferences:

– ATS International Conference 2026. Poster Board #904 titled ‘AGMB-447, an Inhaled LungRestricted TGFβR1/ALK5 Inhibitor Intended for the Treatment of Idiopathic Pulmonary Fibrosis, Shows Robust Anti-Fibrotic Activity and Target Engagement in Preclinical Species and Healthy Subjects’ on Wednesday, May 20, 2026 at 8:15 AM ET in Orlando, FL.
– H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Fireside chat on Tuesday, May 19, 2026 at 1:30 PM ET in New York, NY.
– 2026 RBC Capital Markets Global Healthcare Conference. Fireside chat on Wednesday, May 20, 2026 at 8:00 AM ET in New York, NY.
– JPM European Healthcare Symposium. Wednesday, June 10, 2026 in London, UK.
– BIO International Convention. Monday, June 22 – Thursday, June 25, 2026 in San Diego, CA.
– 2026 Leerink Partners Therapeutics Forum. One-on-one investor meetings on Wednesday, July 15, 2026 in Boston, MA.

— Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208
Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029
— Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase
2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD)
— On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic
Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026
— Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with
Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Half of
2026

Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (”’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company’s investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This patent provides intellectual property (IP) protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions.